North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930
Recruiting
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
Gender:
ALL
Ages:
Between 6 months and 72 months
Trial Updated:
07/21/2025
Locations: UNC Hospitals, The Univ of NC at Chapel Hill, Chapel Hill, North Carolina
Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
Register for Updates
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296
Recruiting
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Endometrial Adenocarcinoma
Register for Updates
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of North Carolina at Chapel Hill /ID# 269563, Chapel Hill, North Carolina
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
NCT05415358
Recruiting
The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Atrium Health Levine Cancer, Charlotte, North Carolina
Conditions: Lung Cancer, Nonsmall Cell
Register for Updates
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of neladalkib and will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of neladalkib in patients with advanced ALK+ solid tumors. Phase... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/21/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617
Recruiting
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
07/21/2025
Locations: Duke University Clinical Research at Pickett Road, Durham, North Carolina
Conditions: Seizures, Lennox Gastaut Syndrome
Register for Updates
REMASTer: REcurrent Brain Metastases After SRS Trial
NCT05124912
Recruiting
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
Register for Updates
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
NCT05005403
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of Azirkitug (ABBV-514) as a monotherapy and in combination with Budigali... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Carolina BioOncology Institute /ID# 232597, Huntersville, North Carolina
Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Register for Updates
Xenon MRI Pulm Hypertension
NCT04991454
Recruiting
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/21/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Register for Updates
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436
Recruiting
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of North Carolina /ID# 233313, Chapel Hill, North Carolina
Conditions: Chronic Lymphocytic Leukemia (CLL)
Register for Updates
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
NCT04798261
Recruiting
The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: NC Heart and Vascular Research, Raleigh, North Carolina
Conditions: Pulmonary Embolism
Register for Updates
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309
Recruiting
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastr... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/21/2025
Locations: Research Site, Durham, North Carolina
Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Register for Updates